BOTHELL, Wash., June 30 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today that it has been selected to join the Russell 3000(R) Index. The Company's addition to the Russell 3000 Index was made effective following the market close on Friday, June 27. Selection to the Russell 3000 index means Cardiac Science is automatically included in the Russell 2000(R) Index, which measures the performance of approximately 2,000 small-cap U.S. securities.
"We believe our inclusion in the Russell indexes will provide our company with greater visibility to a broader range of potential investors," said John Hinson, president and chief executive officer of Cardiac Science.
The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies, and is constructed to provide a comprehensive, unbiased and stable barometer of the broad market. The Index is reconstituted annually. The Russell 2000 Index is a subset of the Russell 3000 Index.
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of
advanced diagnostic and therapeutic cardiology devices and systems,
including automated external defibrillators (AEDs), electrocardiograph
devices (ECGs), cardiac stress systems and treadmills, Holter monitoring
systems, hospital defibrillators, cardiac rehabilitation telemetry systems,
and cardiology data management systems (informatics) that connect with
hospital information (HIS), electronic medical record (EMR), and other
information systems. The Company sells a variety of related products and
consumables, and provides a portfolio of training, maintenance, and support
services. Cardiac Science, the successor to the cardiac businesses that
established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and
Quinton(R) brands, is headquartered in Bothell, Washington. With customers
in more than 100 countries worldwide, the company has operations in North
America, Europe, and Asia. For information, call 425.402.2000 or visit
Company Contact: Investor Contact: Media Contact:
Mike Matysik Jenifer Kirtland or Christopher Gale
Cardiac Science Donald Takaya EVC Group, Inc.
Corporation EVC Group, Inc. (201) 646-5431
Sr. Vice President (415) 896-6820 (203) 570-4681
and CFO email@example.com
|SOURCE Cardiac Science Corporation|
Copyright©2008 PR Newswire.
All rights reserved